Odysight.ai (NASDAQ:ODYS) received a purchase order valued at approximately $0.3 million (NIS 1.0 million) from Elbit Systems to supply its specialized health monitoring software.
Sono-Tek (NASDAQ:SOTK) reported fiscal first-quarter 2027 results for the period ended May 31, 2026, with net sales increasing 10% to $5.66 million, mainly driven by demand from medical markets.
Diana Shipping (NYSE:DSX), the largest shareholder of Genco Shipping & Trading (NYSE:GNK), urged Genco investors to tender shares by July 10, 2026, at 5:00 p.m. Eastern Time under its acquisition proposal.
OR Royalties (NYSE:OR) generated 20,757 gold equivalent ounces in preliminary second-quarter asset deliveries to drive strong cyclical performance gains across its streaming portfolio.
AerCap Holdings (NYSE:AER) signed lease agreements with China Southern Group for three Boeing 777-300ERSF converted freighter aircraft to support the airline’s cargo operations.
BioLineRx (NASDAQ:BLRX) and Hemispherian reported positive preclinical data from a patient-derived ovarian cancer xenograft model showing a strong therapeutic synergy between its small-molecule candidate GLIX1 and the approved PARP inhibitor olaparib.
Keenova Therapeutics (NYSE:MNK) reported positive top-line Phase 3 clinical trial results for its injectable enzyme therapy XIAFLEX in adult patients suffering from progressive plantar fibromatosis.
Spire Global (NYSE:SPIR) successfully launched 10 satellites aboard SpaceX’s Transporter-17 rideshare mission, expanding its space-based data and intelligence capabilities.
Endeavour Silver (NYSE:EXK) reported a 36% year-over-year surge in second-quarter 2026 consolidated production, delivering 3.44 million silver equivalent ounces.
Helen of Troy (NASDAQ:HELE) reported fiscal first-quarter 2027 results for the three months ended May 31, 2026, with consolidated net sales increasing to $402.1 million from $371.7 million in the prior-year period.
Himalaya Shipping (NYSE:HSHP) achieved average time charter equivalent earnings of approximately US$52,900 per day gross during June 2026, including average daily scrubber benefits of US$1,300.
Satellos Bioscience (NASDAQ:MSLE) reported positive six-month interim data from its open-label Phase 2 TRAILHEAD clinical study evaluating its investigational oral drug candidate SAT-3247 in adults with Duchenne muscular dystrophy.
